Even though the immuno-oncology (IO) era has achieved many successes, some signs of
research development deceleration are arising. Recently, the number of FDA …

Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple
tumor types, providing unprecedented survival in some patients. Despite the characteristic …

Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …

Novel patterns of response and progression to immunotherapy have been reported that are
not observed with conventional cytotoxic or targeted anticancer treatments. A major …

PURPOSE Limited data exist on the optimal duration of immunotherapy, including for non–
small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a …

Great advances in immune checkpoint blockade have resulted in a paradigm shift in patients
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …

Background Pembrolizumab improved progression-free survival and overall survival versus
ipilimumab in patients with advanced melanoma and is now a standard of care in the first …

Background Nivolumab showed improvement in overall survival (OS) in ATTRACTION-2, the
first phase 3 study in patients with gastric/gastroesophageal junction (G/GEJ) cancer treated …

Objective Immune checkpoint inhibitors (ICI s) for cancer therapy frequently induce immune‐
related adverse effects (IRAE s). Therefore, most patients with preexisting autoimmune …

In the past 10 years, a deeper understanding of the immune landscape of cancers, including
immune evasion processes, has allowed the development of a new class of agents. The …